Equities

SIGA Technologies Inc

SIGA:NMQ

SIGA Technologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.06
  • Today's Change-0.48 / -6.37%
  • Shares traded444.20k
  • 1 Year change+43.20%
  • Beta0.9058
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.

  • Revenue in USD (TTM)172.96m
  • Net income in USD83.97m
  • Incorporated1995
  • Employees45.00
  • Location
    SIGA Technologies Inc31 East 62Nd StreetNEW YORK 10065United StatesUSA
  • Phone+1 (212) 672-9100
  • Fax+1 (212) 697-3130
  • Websitehttps://www.siga.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revance Therapeutics Inc247.00m-180.81m359.42m597.00------1.46-1.91-1.952.55-1.550.4971.036.71413,740.40-36.38-55.55-43.47-63.2072.61---73.20-304.963.05-15.401.58--76.55128.849.10---0.3022--
Biostem Technologies Inc131.44m7.87m402.62m67.0073.8822.2349.813.060.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Rigel Pharmaceuticals Inc157.47m3.88m438.99m147.00115.15--75.712.790.21670.21678.98-0.8311.243.065.821,071,252.003.05-28.825.10-47.2689.4397.882.46-35.761.871.691.32---2.7921.3057.16--68.45--
Theravance Biopharma Inc62.02m-45.65m444.21m99.00--2.29--7.16-0.924-0.9241.253.960.1534--4.12626,434.30-11.29-40.51-12.00-48.50-----73.61-305.27----0.1305--11.84-0.995640.54---19.24--
Aquestive Therapeutics Inc58.90m-35.19m462.27m135.00------7.85-0.4514-0.45140.7297-0.49820.69542.566.46436,296.30-41.55-76.63-54.06-123.8569.3964.24-59.75-102.955.91-2.72----6.09-5.5985.54---11.42--
Zevra Therapeutics Inc23.99m-65.75m471.46m65.00--11.58--19.66-1.67-1.670.61060.77340.1919--2.09369,015.40-52.61-32.11-65.34-39.8971.78---274.10-128.42---112.940.6423--170.26---72.00--69.75--
Amylyx Pharmaceuticals Inc196.49m-259.47m478.62m384.00--2.46--2.44-3.82-3.822.872.860.54792.5612.64511,679.70-72.35---84.00--78.88---132.05--4.55--0.00--1,612.94--124.84------
Xeris Biopharma Holdings Inc181.41m-59.56m488.72m377.00------2.69-0.4215-0.42151.28-0.12950.54930.74284.99481,201.60-18.04-43.60-23.57-56.5783.7278.23-32.83-143.081.69-1.591.09--48.68131.5034.23--8.43--
Esperion Therapeutics Inc295.45m-86.77m494.49m240.00------1.67-0.6585-0.65851.72-1.891.100.82755.351,231,046.00-32.41-69.45-74.85-101.8181.58---29.37-147.441.370.3253----54.14--10.45------
SNDL Inc654.42m-79.32m528.35m2.52k--0.6087--0.8073-0.3027-0.30272.493.270.60624.9836.38260,104.70-7.61-24.44-8.22-27.9425.6922.49-12.55-62.174.16--0.114--27.63--49.83------
SIGA Technologies Inc172.96m83.97m538.12m45.006.493.216.373.111.161.162.412.351.020.586623.093,843,484.0049.5222.3456.2127.5682.0088.6548.5541.145.65--0.0029.5126.31-21.75100.76-30.57-26.67--
Elite Pharmaceuticals Inc66.45m19.58m577.94m64.0028.289.9227.448.700.01910.01910.0640.05450.98922.914.981,038,252.0029.1519.0736.1824.2945.2746.6329.4720.772.091.440.13890.0065.7949.55464.56--111.50--
ASP Isotopes Inc2.30m-27.05m588.52m76.00--39.15--256.36-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Sinovac Biotech Ltd429.20m-130.73m639.90m3.04k------1.49-1.31-1.314.3186.810.03220.20191.08141,325.00-2.2336.14-3.3058.3792.0990.77-69.1965.8711.24--0.0262---69.9714.31-198.16--91.80--
Emergent Biosolutions Inc1.13bn-208.80m648.58m1.60k--1.27--0.5763-4.10-4.1021.199.400.66782.216.66703,437.50-12.39-2.94-16.86-3.6633.5153.24-18.55-5.951.47-1.190.5658---6.106.05-259.40---4.29--
Data as of Nov 12 2024. Currency figures normalised to SIGA Technologies Inc's reporting currency: US Dollar USD

Institutional shareholders

25.28%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20243.11m4.36%
First Wilshire Securities Management, Inc.as of 30 Jun 20242.64m3.69%
The Vanguard Group, Inc.as of 30 Jun 20242.33m3.26%
AltraVue Capital LLCas of 30 Jun 20242.18m3.05%
Dimensional Fund Advisors LPas of 30 Sep 20241.81m2.54%
Van Lanschot Kempen Investment Management NVas of 30 Jun 20241.72m2.41%
SSgA Funds Management, Inc.as of 30 Jun 20241.13m1.58%
D. E. Shaw & Co. LPas of 30 Jun 20241.07m1.51%
Geode Capital Management LLCas of 30 Jun 20241.05m1.47%
Federated MDTA LLCas of 30 Jun 20241.01m1.42%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.